Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Michal Hofer *, Zuzana Hoferová and Martin Falk

Department of Cell Biology and Radiobiology, Institute of Biophysics, v.v.i., Czech Academy of Sciences, Královořepolská 135, 61265 Brno, Czech Republic; hoferovaz@centrum.cz (Z.H.); falk@ibp.cz (M.F.)

* Correspondence: hofer@ibp.cz; Tel.: +420-541-517-171; Fax: +420-541-211-293

Received: 5 June 2017; Accepted: 26 June 2017; Published: 28 June 2017

Abstract: In recent times, cytokines and hematopoietic growth factors have been at the center of attention for many researchers trying to establish pharmacological therapeutic procedures for the treatment of radiation accident victims. Two granulocyte colony-stimulating factor-based radiation countermeasures have been approved for the treatment of the hematopoietic acute radiation syndrome. However, at the same time, many different substances with varying effects have been tested in animal studies as potential radioprotectors and mitigators of radiation damage. A wide spectrum of these substances has been studied, comprising various immunomodulators, prostaglandins, inhibitors of prostaglandin synthesis, agonists of adenosine cell receptors, herbal extracts, flavonoids, vitamins, and others. These agents are often effective, relatively non-toxic, and cheap. This review summarizes the results of animal experiments, which show the potential for some of these untraditional or new radiation countermeasures to become a part of therapeutic procedures applicable in patients with the acute radiation syndrome. The authors consider β-glucan, 5-AED (5-androstenediol), meloxicam, γ-tocotrienol, genistein, IB-MECA (N6-(3-iodobezyl)adenosine-5'-N-methyluronamide), Ex-RAD (4-carboxystyryl-4-chlorobenzylsulfone), and entolimod the most promising agents, with regards to their contingent use in clinical practice.

Keywords: acute radiation syndrome; radioprotectors; radiomitigators; hematopoiesis

1. Introduction

Radiation accidents, as well as contingent terrorist attacks using ionizing radiation sources, can result in serious health damage whose manifestations are designated as the acute radiation syndrome (ARS). Depending on the absorbed radiation dose, the manifestation of ARS takes place in different organ systems as individual organ syndromes, namely hematopoietic, gastrointestinal, cutaneous, and neurovascular [1]. Not surprisingly, both the topics of “radioprotectors for use prior to irradiation” and “therapeutic agents for post-exposure treatments” (radiomitigators) enjoy top priority among the research areas for radiological nuclear threat countermeasures [2]. Although endeavors aimed at developing medically effective radiation countermeasures (including both the radioprotectors and radiomitigators) were initiated more than fifty years ago, only two radiation countermeasures, namely Neupogen® and Neulasta®, have been recently approved by the United States Food and Drug Administration (FDA) as radiomitigators [3,4].

Hematopoietic growth factors are proteins that regulate growth and differentiation of red and white blood cells. Cytokines are proteins of low molecular weight that exert a stimulating or inhibiting influence on the proliferation, differentiation, and function of cells of the immune system. Both Neupogen® and Neulasta® are granulocyte colony-stimulating factor (G-CSF)-based drugs, made to improve the pharmacokinetic properties of G-CSF [5]. G-CSF belongs to hematopoietic growth
factors which, together with cytokines, have been intensively tested and evaluated for modulation of the acute radiation damage e.g., [6,7], and have also been used for the treatment of radiation accident victims [8]. Nevertheless, comparable attention has also been paid by radiation researchers to substances not counted among hematopoietic growth factors or cytokines and/or their derivatives. As shown mostly in animal studies, there exists a wide spectrum of such substances which are often effective in modulating ARS, as well as being relatively non-toxic and cheap. This review summarizes important pieces of information on these agents and emphasizes their potential for incorporation into the treatment schemes of patients with ARS.

2. Immunomodulators

Immunotherapy is defined as “treatment of disease by inducing, enhancing, or suppressing an immune response”. A number of immunomodulators inducing and/or enhancing the immune response, which are represented by an array of various preparations, have been tested with the aim of modulating ARS.

2.1. β-Glucan

Glucans, especially β-glucan, belong to the most studied immunomodulators both generally, and in the field of the pharmacological modulation of radiation damage. β-glucans are known as cell wall constituents of bacteria [9], yeast [10], fungi [11], and plants [12]. Early hematological studies have revealed that β-glucan stimulates proliferation of non-irradiated mouse pluripotent stem cells, as well as of several hematopoietic progenitor cell lineages, namely those of granulocytes, granulocytes/macrophages, macrophages, and erythrocytes e.g., [13]. Several studies performed, especially by Patchen and McVittie (Bethesda, MD, USA) and Hofer and Pospíšil (Brno, Czech Republic), have shown that the hematopoiesis-stimulating effects of β-glucan can be successfully employed in treating hematopoietic ARS in mice. An important feature of the use of β-glucan in irradiated experimental was the possibility of its profitable administration both prior to and after irradiation, i.e., as radioprotector or radiomitigator [14–25]. The use of β-glucan in combined-treatment regimen has also turned out to be successful—mutually potentiating effects of β-glucan have been observed following its combined administration with the chemical radioprotectors cystamine or WR-2721 [26,27]. A three-drug combination treatment of β-glucan, WR-2721, and selenium has shown a positive outcome as well [28]. β-glucan has also been successfully combined with G-CSF [29] or diclofenac, a cyclooxygenase inhibitor [30,31]. Many details concerning the experiments summarized in this paragraph, including information about the enhancement of survival of lethally irradiated experimental animals by β-glucan in some of these studies, can be found in a separate detailed review [32].

Later studies have added new understanding and have confirmed the above-mentioned ability of β-glucan to stimulate hematopoiesis and enhance survival in radiation-exposed animals. In 2006, Cramer et al. [33] revealed the role of complement in mediating the hematopoietic recovery after radiation-induced injury. In 2011, Salama [34] emphasized the possibility to administer, with a positive outcome, β-glucan to irradiated rats orally. In their thorough study from 2013, Pillai and Devi [35] examined the effects of pre-irradiation β-glucan administration, in which cytological and biochemical parameters were included, besides post-irradiation survival and hematopoiesis. Further, apart from their promising findings, they also examined the non-toxicity of β-glucan. In their review from 2009 on the biological activities of β-glucan, Rondanelli et al. [36] stressed the contingent use of β-glucan both as a prophylactic and as a therapy in cases of nuclear emergencies.

2.2. 5-Androstenediol (5-AED)

5-androstenediol (5-AED) is a natural adrenocortical steroid hormone. AED has been found to stimulate the innate immune system and, therefore, it is counted among immunomodulators. The first report on the hematopoietic and immune system stimulation observed in γ-irradiated mice is from 2000—both pre- and post-irradiation administration of 5-AED has produced stimulation of myelopoiesis and enhancement of resistance to infection in irradiated animals [37]. In the following
study, a stimulation of cells of the immune system, like monocytes, natural killer cells, eosinophils, and basophils, has been observed following administration of 5-AED [38]. Further experiments have revealed that 5-AED is effective at both subcutaneous and oral administration routes, and that the radioprotective efficacy of the drug is accompanied by low toxicity [39]. As one of the mechanisms of the hematopoiesis-stimulating effects of 5-AED, an induction of amplified production of G-CSF (when 5-AED was administered either as a radioprotector or as a radiomitigator) has been reported [40]. Comparative experiments have shown that the radioprotective efficacy of 5-AED is unique among ten selected different steroids [41]. Subsequently, studies on mice have been supplemented by experiments on non-human primates—a multilineage stimulation of hematopoiesis in irradiated rhesus monkeys has been found [42]. This knowledge has been obtained even when the irradiated monkeys were otherwise clinically unsupported [43]. An induction of nuclear factor-κB activation has been found as the mechanism of enhanced survival of irradiated human hematopoietic progenitors in the presence of 5-AED [44]. To further elucidate the mechanisms of hematopoiesis-stimulating effects of 5-AED, expression of a number of hematopoietic growth factors and cytokines in 5-AED-treated mice has been evaluated. An increased expression following the injection of 5-AED has been referred to as granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-6 (IL-6), and interleukin-10 (IL-10) in the spleen, as well as to G-CSF, GM-CSF, interferon-γ (IFN-γ), thrombopoietin (TPO), IL-2, IL-3, IL-6, IL-10, and interleukin-12 (IL-12) in the bone marrow [45]. The significant role of G-CSF in mediating the effects of 5-AED has been confirmed by a study in which G-CSF antibody was used for abrogating the radioprotective efficacy of 5-AED [46]. A synergistic action of 5-AED and TPO has been shown in mice suffering from hematopoietic ARS [47]—in this study, a 20.1-fold increase in the life-saving short-term repopulating cells in the bone marrow has been observed in the 5-AED + TPO-treated mice [47]. A sequential injection of 5-AED, comprising one pre-irradiation administration and twice weekly injections for three weeks post-irradiation, have been reported to be very successful in treating the radiation-induced myelosuppression [48]. The authors have stated that “5-AED can be a significant therapeutic candidate for the management of ARS, particularly in a mass casualty scenario where rapid and economic intervention is important [47]”. 5-AED is now in advanced development and has been granted FDA investigational new drug (FDA IND) status [49]. First positive clinical observations on the safety, tolerability, and hematologic activity of 5-AED in healthy adults have been already reported as well [50].

2.3. Other Immunomodulators

This paragraph summarizes data on another immunomodulators tested from the point of view of their abilities to modulate ARS.

Perhaps the oldest immunomodulator studied as a radioprotector is endotoxin, a bacterial lipopolysaccharide. As early as 1958, a report on decreased X-ray mortality in endotoxin-treated mice was published [51]. As an important manifestation of its radioprotective action, an increased number of spleen colony-forming units (used for expression of numbers of hematopoietic stem cells) in endotoxin-pre-treated irradiated mice has been reported [52]. A large amount of literature has been published on the endotoxin’s radioprotective properties. However, because of its severe side effects [53], endotoxin has been gradually abandoned as a potentially usable drug in irradiated humans. On the contrary, reduction of endotoxemia has been considered a desirable effect of drugs used for the treatment of ARS, e.g., with antibiotics [54].

Broncho-Vaxom® is a bacterial lysate. It has been shown to significantly enhance post-irradiation survival in several mouse strains [55]. Subsequent studies have revealed positive hematological effects of Broncho-Vaxom® in sublethally irradiated mice [56–58]. Broncho-Vaxom® has been also tested with success in its combined administration with the chemical radioprotector WR-2721 (amifostine) [59,60]. Broncho-Vaxom® has been found to act radioprotectively when administered pre-irradiation [55–60], as well as a radiomitigator following its post-irradiation administration [60]. In a later study, Broncho-Vaxom® has been administered to rats in repeated injections comprising one pre-irradiation
dose and repeated post-irradiation doses in the course of a three-week period of fractionated irradiation. The drug has been reported to enhance the antioxidant system and to increase the serum 𝛾-globulin content [61].

Trehalose dimycolate is a glycolipid molecule found in the cell wall of Mycobacterium tuberculosis. It has been reported to enhance resistance to infection in irradiated neutropenic mice [62]. A synthetic derivative of trehalose dimycolate (trehalose dicornomycolate) has been tested with success in mice with sepsis following irradiation and trauma [63].

An interesting radioprotective combination is that of the oligoelements selenium, zinc, and manganese administered concomitantly with Lachesis muta venom. This combination is called "immunomodulator" by the authors and has been tested in both mice [64] and rats [65].

Peptidoglycan is a bacteria cell wall polymer consisting of sugars and amino acids. In a recent study, peptidoglycan was observed to promote survival, as well as to ameliorate intestinal and bone marrow damage in irradiated mice when injected after irradiation [66]. These parameters have been found to be synergistically promoted when the mice were given the chemical radioprotectant WR-2721 pre-irradiation and peptidoglycan post-irradiation [66]. Apart from radioprotection of the hematopoietic and gastrointestinal tissues, a complete prevention of permanent submandibular gland radiation-induced alterations has been reported, following the administration of this radiomodifying mixture of compounds [66].

Other recent studies have been concerned with Sipunculus nudus (a species of unsegmented marine worms) polysaccharide. Sipunculus nudus polysaccharide, consisting of mannose, rhamnose, galacturonic acid, glucose, arabinose, and fucose, administered before irradiation, has been found to significantly increase survival of irradiated mice [67]. When the substance was tested in Beagle dogs, Sipunculus nudus polysaccharide-treated animals have shown, among others, an improved blood picture and an improved hematopoietic activity in the bone marrow [68]. Synergistic effects have been reported for the radioprotective combination of the Sipunculus nudus polysaccharide, WR-2721, recombinant human interleukin-11 (rhIL-11), and recombinant human G-CSF (rhG-CSF) in radiation-injured mice [69]. Marked antioxidant effects of Sipunculus nudus polysaccharide [67], and its efficacy following its oral administration [68], have been emphasized.

3. Prostaglandins and Inhibitors of Prostaglandin Production

Quite surprisingly, both prostaglandins, especially prostaglandin E₂ (PGE₂), and inhibitors of prostaglandin production (cyclooxygenase (COX) inhibitors), have been successfully tested regarding their abilities to support recovery of experimental animals from ARS. Therefore, both groups of substances are dealt with in the same section.

Several studies from the 1980s showed radioprotective effects of prostaglandins, particularly PGE₂ and a synthetic derivative of prostaglandin E₁, misoprostol, on irradiated gastrointestinal tracts [70–72]. These effects might be ascribed to the subsequently confirmed protective action of prostaglandins on the gastrointestinal tissues [73,74]. However, at the approximately same time, articles showing that PGE₂ stimulates and/or protects erythroid and multilineage hematopoietic progenitor cells [75–77] also appeared. Nevertheless, findings on inhibition of myelopoiesis in vivo by PGE₂ were also published at that time [78,79].

The results mentioned [78,79] help to justify the findings obtained when the action of inhibitors of prostaglandin production (COX inhibitors, non-steroidal anti-inflammatory drugs) in irradiated experimental animals was evaluated. In earlier studies, the radiomodifying effects of non-selective COX inhibitors, inhibiting the synthesis of both cyclooxygenase-1 (COX-1), expressed constitutively in a variety of tissues including the gastrointestinal tract, and cyclooxygenase-2 (COX-2), was tested. This is inducible and responsible for the production of prostaglandins during inflammatory states [80]. In sublethally irradiated experimental animals, hematopoiesis-stimulating effects of non-selective COX inhibitors have been observed when they were administered pre- or post-irradiation, or in the course of the fractionated radiation regimen [81–90]. However, administration of non-selective COX inhibitors...
has also been connected to the occurrence of a rather high incidence and intensity of undesirable side effects, especially on the gastrointestinal tissues [90], and a reduced survival of lethally irradiated animals [91,92]. Numerous details on the effects of non-selective COX inhibitors in irradiated animals can be found in an earlier detailed review [93].

Later investigations on the radiomodifying action of COX inhibitors have used a representative of selective COX-2 inhibitors, meloxicam, whose administration preserves the activity of COX-1 and maintains the protective action of prostaglandins in the gastrointestinal tissues [73,74]. Meloxicam has been shown not only to support hematopoiesis in irradiated mice [94,95], but also to enhance the post-irradiation survival of the animals, namely when administered in a mere single dose 1 h after a lethal irradiation [96]. Thus, favorableness of the use of selective COX-2 inhibitors as radiomitigators has been confirmed.

In a recent study, Hoggatt re-opened investigations on hematological and radiomodifying effects of pharmacological interventions into the metabolism of PGE\(_2\). They stated that PGE\(_2\) enhances hematopoietic stem cell homing, survival, and proliferation [97]. Taking into account all of the available knowledge on the modulation of PGE\(_2\) signaling post-irradiation, as well as their own experimental results, Hoggatt et al. found that an increased survival and stimulation of hematopoiesis in irradiated mice can be obtained both by an administration of PGE\(_2\), and following the treatment with the selective COX-2 inhibitor meloxicam, but that the effectiveness of the therapies depends on the timing of the injections [98].

### 4. Herbal Extracts

Herbal extracts tested for radioprotective and radiomitigating properties comprise preparations from a number of plants. Their action is complex and comprises their antiemetic activity, anti-inflammatory activity, antimicrobial activity, antioxidant activity, hematopoietic stimulation, immunostimulant activity, metal chelation activity, and wound healing activity [99]. In a thorough review from 2005, radioprotective/radiomodifying effects of the extracts from the following plants are summarized with a number of citations: Acanthopanax senticosus, Aegle marmelos, Ageratum conyzoides, Allium cepa, Allium sativum, Aloe arborescens, Amaranthus paniculatus, Angelica sinensis, Archangelica officinalis, Centella asiatica, Curcuma longa, Gingko biloba, Glycyrrhizza glabra, Hipophae rhamnoides, Hypericum perforatum, Lycium chinense, Mentha arvensis, Mentha piperita, Moringa olefera, Ocimum sanctum, Panax ginseng, Podophyllum hexandrum, and Tinospora cordifolia [99]. Generally, herbal extracts are considered successful in treating symptoms of ARS, and their research has continued until the present time. e.g., an extract from Cordyceps sinensis has been observed to protect against both the bone marrow and intestinal radiation-induced injuries [100]. Pre-irradiation administration of an extract from Podophyllum hexandrum has shown radioprotective efficacy, which has been further enhanced by post-irradiation application of an extract from Picrorhizza kurroa [101]. A semi-purified fraction of Podophyllum hexandrum, REC-2001, has been shown to significantly enhance survival of lethally irradiated mice [102]. Stimulatory effects in both the immune tissues in irradiated mice have been reported following the administration of the extract from Vernonia cinerea [103]. Recently, a potent radioprotective effect of a herbal drug prepared from Rosa canina, Urtica dioica, and Tanacetum vulgare, has been observed [104].

### 5. Amifostine

Amifostine (WR-2721) will be dealt with here briefly. Amifostine has been the most exhaustively studied classical chemical radioprotector from the point of view of its ability to protect against ARS because of its high radioprotective efficacy, as summarized in many reviews e.g., [105–107]. For interested readers, we refer them to a rich literature on amifostine and other chemical radioprotectors. Despite the comprehensive number of studies, amifostine has not been approved for the treatment of ARS in humans because of its undesirable side effects, and has found its use in radiation oncology [108,109]. These issues are, however, outside the topic of this review. Nevertheless, attention is still paid to amifostine
from the point of view of its contingent use in treating of ARS—successful attempts have been made recently when administering mice with low doses of amifostine (30 or 50 µg/kg) plus γ-tocotrienol in a combined prophylactic modality [110]. Combined approaches using low amifostine doses might enable the use of this radioprotector in humans in the treatment of ARS.

6. Antioxidants

A rather wide spectrum of substances, mostly naturally occurring ones, will be addressed in this section Their common feature their ability to protect against or to treat radiation damage by scavenging radiation-induced free radicals. These natural antioxidants are generally less effective radioprotectors in comparison with amifostine and other classical chemical radioprotectors, but may provide a longer window of protection [111] and are often non-toxic.

6.1. Vitamin E Family Members

Vitamin E represents a family of compounds that is divided into two subgroups called tocopherols and tocotrienols; both function as important antioxidants [112]. They differ chemically in that tocotrienols contain three double bonds in their isoprenoid side chain, while tocopherols do not [113]. Tocotrienols have superior antioxidant activity compared with tocopherols [114]. There exist ample literature on the radioprotective and radiomitigating action of vitamin E family members, whose detailed summarization exceeds the extent of this review. Therefore, for each subgroup, selected examples of experimental findings will be shown and, finally, further research literature will be recommended.

Concerning tocopherols, three compounds have been tested for their contingent modulating effects on ARS. α-tocopherol has been found to enhance both survival and ARS symptoms when administered both pre- and post-irradiation [115–117]. As the mechanism of the α-tocopherol’s radiomitigative effect, an enhancement of cell-mediated immunity has been proposed [118]. α-tocopherol-mono-glucoside is a water-soluble glycosylated derivative of α-tocopherol. When administered post-irradiation, α-tocopherol-mono-glucoside has been demonstrated to increase survival [119] and to stimulate hematopoiesis in mice [120,121]. Attention has also been paid to α-tocopherol succinate, the hemisuccinate ester derivative of α-tocopherol. α-tocopherol succinate has been observed to enhance survival of irradiated mice, including mice irradiated with doses causing the gastrointestinal ARS [122,123]. As for hematopoiesis-modulating action of α-tocopherol succinate, it has been reported that its radioprotective efficacy is mediated through the induction of G-CSF production [124].

Regarding tocotrienols, two vitamin E family members have been investigated from the point of view of their abilities to influence ARS, namely δ-tocotrienol and γ-tocotrienol. δ-tocotrienol possess very high antioxidant activity [125], and has been also shown to protect hematopoiesis and increase survival of irradiated mice [126,127]. In recent years, attention has been paid especially to γ-tocotrienol, another vitamin E derivative with a high antioxidant ability [128]. From the perspective of its contingent use in treating ARS, the hematopoiesis-stimulating [129] and survival-enhancing efficacy of γ-tocotrienol [130] should be emphasized. An important role of G-CSF in mediating the radioprotective effects of γ-tocotrienol has been shown when using G-CSF antibodies [131]. Recently, the radioprotective efficacy of γ-tocotrienol has also been confirmed in non-human primates [132].

Many more details and literature on the radiobiological properties of tocopherols and tocotrienols can be found in a 2013 review [133]. A recent separate detailed review has been devoted to γ-tocotrienol [134]. It has been stated that a single administration of γ-tocotrienol without any supportive care was equivalent, in terms of improving hematopoietic recovery, to multiple doses of Neupogen and Neulasta (both G-CSF-based drugs) with full supportive care (including blood products) in the non-human primate model [summarized in 134]. γ-tocotrienol has been categorized by Singh et al. among “promising molecules at advanced stages of development” [49].
6.2. Selenium-Containing Compounds

Several selenium derivatives have been investigated for their radioprotective effects; perhaps the most intensively studied selenium compounds have been sodium selenite and selenomethionine. Selenomethionine, which is a naturally occurring derivative of low toxicity, can be found in soy, grains, and legumes [135]. Expressive and significant survival benefits in irradiated mice have been obtained when either sodium selenite or selenomethionine were administered to mice 24 h or one hour before, or 15 min after, irradiation [136]. Concerning the mechanisms of the radiomitigating effects of the post-irradiation administration of selenium, an enhancement of functions of immunocompetent cells has been proposed [137]. There exists a great amount of research on the ability of selenium compounds to modulate radiation damage where many details can be found [138,139]. Recent findings showing that selenium protects intestinal tissue against ionizing radiation [140] suggest the usefulness of selenium administration in the intestinal ARS.

6.3. Other Antioxidative Compounds

Many antioxidative compounds have been tested for their radiomodifying properties. This paragraph gives examples of some of them. Their common characteristics are mostly very low toxicity, as well as the possibility of their peroral administration.

Vitamin C (ascorbic acid) has been reported to improve the bone marrow status and survival of irradiated mice [141]. Further, mice given peroral vitamin A or its precursor, β-carotene, have shown reduced morbidity and mortality [142]. Recently, protective effects of α-lipoic acid on radiation-induced small intestine injury has been found in mice [143], suggesting the potential use of this antioxidative compound in the treatment of the intestinal ARS.

An interesting contribution to the topic of the combined pharmacological approach to the modulation of radiation damage has been provided by Wambi et al. who tested the efficacy of a dietary supplement consisting of L-selenomethionine, vitamin C, vitamin E succinate, α-lipoic acid, and N-acetyl-cysteine. This supplement positively influenced hematopoiesis and survival of irradiated mice when given either before or after their irradiation with X-rays [144], or when administered after exposure of the animals to proton irradiation [145].

Antioxidant nutrients are considered in more detail in a review [146].

7. Other Compounds Tested as Radioprotectors or Radiomitigators

7.1. Genistein

Genistein is a soy isoflavone. Its effects in an irradiated organism are probably complex, including antioxidative [147] and hematopoiesis-stimulating actions [148].

In a report from 2003, genistein has been shown to significantly increase survival of mice when administered in a single preirradiation subcutaneous injection [149]. A complex enhancement of a wide spectrum of bone marrow and blood parameters has been reported when genistein was administered once daily for seven consecutive days before a whole-body irradiation [148]. Hematopoiesis-stimulating effects of genistein have also been confirmed following its single pre-irradiation dose [150]. Details on the radiomodifying actions of genistein are summarized in a separate review [151].

Genistein, administered pre-irradiation has also been successfully combined with captopril, an angiotensin converting enzyme, given to mice in their drinking water on days 1 to 30 after irradiation, as shown by stimulated hematopoiesis and increased survival of mice. For example, whereas the whole-body dose of 8.25 Gy resulted in 0% survival in untreated mice, administration of genistein, captopril, or genistein + captopril increased survival to 72%, 55%, and 95%, respectively [152]. To overcome genistein’s low water solubility, a nanoparticle suspension of genistein has been formulated. This form of genistein has also shown protection of hematopoietic system in irradiated mice [153]. Genistein has been granted FDA IND status [49].
7.2. Adenosine Receptor Agonists

The combination of dipyridamole (DP), a drug inhibiting the cellular uptake of adenosine [154], and adenosine monophosphate (AMP), an adenosine prodrug [155], has been used in an attempt to enhance the receptor action of adenosine in a series of studies on irradiated mice. The results of these studies have clearly shown that the pre-irradiation combination of DP and AMP stimulates hematopoiesis and increases survival under conditions of single [156–159], as well as fractionated irradiation [159,160].

Adenosine receptors, activated non-selectively in the experiments mentioned [155–160], exist in four subtypes. Further experimentation, using agonists selected for the individual subtypes, has been aimed at finding out whether stimulation of one of the four subtypes is responsible for the previously observed hematopoiesis-stimulating and radioprotective effects. These experiments are described in detail in a separate review [161]. It follows from the findings that IB-MECA (N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide) stimulates the cycling of hematopoietic progenitor cells [162]. Subsequently, IB-MECA has been shown to support hematopoiesis, as well as the hematopoiesis-stimulating effects of G-CSF in sublethally irradiated mice [163]. Mutually potentiating effects on hematologic parameters in irradiated mice have been also observed following a concomitant administration of IB-MECA and meloxicam, a cyclooxygenase-2 inhibitor, in a post-irradiation treatment regimen [164]. This series of studies has been completed with the finding that IB-MECA and meloxicam, given in the same therapeutic treatment regimen to lethally irradiated mice, enhance the survival of the exposed animals, each alone or in a combination [165].

7.3. More Selected Compounds

Ex-RAD (ON 01210.Na, 4-carboxystyryl-4-chlorobenzylsulfone), is a rather new chemical entity, reported to possess significant radioprotective effects in terms of survival following either subcutaneous [166] or peroral administration routes [167], as well as of ameliorating hematopoietic and gastrointestinal damage [168]. The mechanisms of the radioprotective effects of Ex-RAD involve prevention of p53-dependent and independent radiation-induced apoptosis [162], as well as attenuation of the DNA damage response [169] and the up-regulation of PI3-Kinase/AKT pathways in cells exposed to radiation [170]. Ex-RAD possesses the FDA IND status [49].

Metformin is a biguanide drug used in the treatment of type II diabetes. Recently metformin’s radiomitigating effects when administered 24 h after irradiation alone or in pharmacological combinations [171]. Metformin is approved by FDA for human use and has a well characterized human safety profile [171].

Toll-like receptor 5 (CBLB502, entolimod) is a polypeptide drug derived from salmonella flagellin [172]. It has been shown to enhance survival and protect against hematopoietic and gastrointestinal ARS when administered either before or after irradiation [172,173]. Entolimod has been found to increase the clonogenic potential of the bone marrow cells and to reduce apoptosis in the intestinal crypts [173]. Entolimod has found its use also in mitigation of radiation-induced epithelial damage in a mouse model of fractionated head and neck irradiation [174]. It has been also demonstrated that G-CSF and IL-6 may serve as efficacy biomarkers for this agent [175]. This is an important observation since such biomarkers may be helpful for dose conversion from animal to human, especially in view of the fact that entolimod also possesses the FDA IND status [49].

FGF-2 peptide, a peptide derived from the binding domain of fibroblast growth factor, has been reported to rescue a significant fraction of four strains of mice with the gastrointestinal ARS. Use of FGF-2 peptide has improved crypt survival and repopulation, partially preserved or restored GI function, and has reduced radiation-induced increased plasma endotoxin and pro-inflammatory cytokine levels [176].

Octadecenyl thiophosphate, a small molecule mimic of the growth factor-like mediator lysophosphatidic acid, has been shown to either protect from or mitigate both the hematopoietic and gastrointestinal ARS [177]. Besides direct effects on the gastrointestinal and hematopoietic tissues, octadecenyl thiophosphate has also been found to reduce endotoxin seepage into blood [177].
The gastrointestinal ARS has also been the target of the radioprotective and radiomitigating pharmacological approach using inhibitors of prolyl hydroxylase domain-containing enzymes (PHDs), whose administration has resulted in stabilization of hypoxia-inducible factors (HIFs) protecting important cellular compartments from radiation-induced damage [178]. The role of the PHD/HIF axis in the radiation-induced gastrointestinal toxicity has been recently reviewed and the procedures using PHDs resulting in stabilization of HIFs have been proposed as new class of radioprotectors [179].

8. Remarks to Cutaneous Syndrome of Acute Radiation Syndrome (ARS)

Although the cutaneous syndrome of ARS is clinically relevant both for both the radiation victims and radiotherapy-exposed oncological patients, it will be briefly considered separately. In patients with the cutaneous syndrome, pharmacological therapy applying topical or systemic steroids [180,181], or combined pentoxifylline and vitamin E [182] (for the treatment of late consequences of the radiation damage to the skin) has been used. However, current approaches for the treatment of the cutaneous syndrome consist of, among others, non-pharmacological methods like local injections of bone marrow mesenchymal stem cells [183,184] or adipose tissue-derived stromal/stem cells [185]. A more detailed consideration of therapeutical approaches aimed at treatment of the cutaneous syndrome lies outside of the scope of this article.

Agents mentioned in this review which have been used in attempts to modify the course of the acute radiation syndrome (ARS) (not including hematopoietic growth factors and cytokines) are summarized in Table 1.

| Agent or Group of Agents | Predominant Radiomodifying Effect(s) | Reference Number(s) |
|-------------------------|-------------------------------------|---------------------|
| 4-carboxystyryl-4-chlorobenzylsulfone (Ex-RAD) | Prevention of apoptosis | [49,166–170] |
| 5-androstenediol (5-AED) | Immunomodulator, stimulator of hematopoiesis | [37–50] |
| Adenosine monophosphate (AMP) | Stimulator of proliferation of hematopoietic progenitor cells | [155–160] |
| α-Lipoic acid | Antioxidant | [143,145] |
| Amifostine (WR-2721) | Free radical scavenger | [59,60,66,69,105–110] |
| β-Glucan | Immunomodulator, stimulator of hematopoiesis | [9–36] |
| Broncho-Vaxom | Immunomodulator, stimulator of hematopoiesis | [55–61] |
| Captopril | Vasodilator | [132] |
| Dipyridamole | Enhances adenosine receptor action, stimulator of proliferation of hematopoietic progenitor cells | [154,156–160] |
| Endotoxin | Immunomodulator, stimulator of hematopoiesis | [51–54] |
| FGF-2 peptide | Improvement of regeneration of radiation-induced gastrointestinal damage, reduction of endotoxemia | [176] |
| Genistein | Antioxidant | [49,147–153] |
| Inhibitors of prolyl hydroxylase domain-containing enzymes | Antioxidants | [176,179] |
| Lachesis muta venom | Immunomodulator | [64,65] |
| Manganese-containing compounds | Antioxidants | [64,65] |
| Meloxicam, selective cyclooxygenase-2 inhibitor | Inhibitor of prostaglandin production, stimulator of myelopoiesis | [94–98] |
| Metformin | Antioxidant, modulator of cell renewal | [171] |
| N<sup>6</sup>-(3-iodobenzyl)adenosine-5′-N′-methyuronamide (IB-MECA) | Stimulator of hematopoietic cell proliferation through adenosine receptor action | [161–165] |
| N-acetylcysteine | Antioxidant | [144,145] |
Table 1. Cont.

| Agent or Group of Agents | Predominant Radiomodifying Effect(s) | Reference Number(s) |
|--------------------------|--------------------------------------|---------------------|
| Non-selective cyclooxygenase inhibitors (non-selective non-steroidal anti-inflammatory drugs) | Inhibitors of prostaglandin production, stimulators of myelopoiesis | [81–93] |
| Octadecenyl thiophosphate | Stimulation of hematopoiesis, reduction of endotoxemia | [177] |
| Pentoxifylline | Improvement of blood flow properties | [182] |
| Peptidoglycan | Immunomodulator, ameliorates bone marrow and intestinal radiation-induced damage | [66] |
| Prostaglandins E and their derivatives | Hematopoietic modulators, radioprotectants of intestinal tissues | [70–79] |
| Selenium-containing compounds | Antioxidants | [64,65,135–140] |
| Sipunculus nudus polysaccharide | Immunomodulator, antioxidant | [67–69] |
| Steroids | Antiinflammatory action | [180,181] |
| Toll-like receptor 5 (CBLB502, entolimod) | Stimulation of proliferation of hematopoietic cells, prevention of apoptosis | [49,172–175] |
| Trehalose dimycolate and its derivatives | Immunomodulators | [62,63] |
| Vitamin C (ascorbic acid) | Antioxidant | [141] |
| Vitamin A and its precursor | Antioxidant | [142] |
| Vitamin E and its derivatives | Antioxidants | [49,112–134] |
| Zinc-containing compounds | Antioxidants | [64,65] |

9. Discussion and Conclusions

Though rather rich in content, this review cannot address all publications dealing with the topic of non-hematopoietic growth factor- and non-cytokine-based treatment of ARS. However, it hopefully gives a suitable overview of important pharmacological approaches aimed at protecting from, or mitigating the consequences of, acute radiation doses inducing ARS.

It can be inferred from the literature summarized here that the topic of pharmacological modulation of radiation damage not only has a long history, but is still alive and active. Many compounds seem to be promising from the point of view of their contingent future incorporation into medical procedures aimed at mitigating or protecting from ARS. In the authors’ opinion, β-glucan, 5-AED, meloxicam, γ-tocotrienol, genistein, IB-MECA, Ex-RAD, and entolimod can find their place among the most promising agents, apart from other hopeful compounds recently or currently tested.

An important aspect in considering the contingent use of the individual compounds in human clinical practice is the fact that many of them are non-toxic (or possess only low toxicity), that they are available (or can be made available readily), and that they are often cheap to prepare in even large quantities.

Therefore, the answer to the question from the title of this review, namely is there is a chance for other compounds than hematopoietic growth factors or cytokines in the pharmacological modulation of radiation damage, is “yes, there is a good chance”.

Acknowledgments: This work was supported by the Czech Science Foundation project 16-12454S, Ministry of Health of the Czech Republic (AZV grant no. 16-29835A; all rights reserved) and from the Czech Republic contribution to the Joint Institute for Nuclear Research, Dubna (project of the Czech Plenipotentiary and the 3 + 3 Project for 2015, 2016).

Author Contributions: Michal Hofer designed the manuscript and significantly participated in its writing. Zuzana Hoferová contributed to writing of Part 3 (Prostaglandins and inhibitors of prostaglandin production) and Part 7 (Other compounds tested as radioprotectors or radiomitigators). Martin Falk contributed to writing of Part 5 (Amifostine) and Part 6 (Antioxidants).

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Dörr, H.; Meineke, V. Acute radiation syndrome caused by accidental radiation exposure—Therapeutic principles. BMC Med. 2011, 9, 1–6. [CrossRef] [PubMed]

2. Pellmar, T.C.; Rockwell, S. Priority list of research areas for radiological nuclear threat countermeasures. Radiat. Res. 2005, 163, 115–123. [CrossRef] [PubMed]

3. Singh, V.K.; Romaine, P.L.P.; Newman, V.L.; Seed, T.M. Medical countermeasures for unwanted CBRN exposures: Part II radiological and nuclear threats with review of recent countermeasure patents. Expert Opin. Ther. Pat. 2016, 26, 1399–1408. [CrossRef] [PubMed]

4. Singh, V.K.; Romaine, P.L.P.; Seed, T.M. Medical countermeasures for radiation exposure and related injuries: Characterization of medicines, FDA-approval status and inclusion into the strategic national stockpile. Health Phys. 2015, 108, 607–630. [CrossRef] [PubMed]

5. Strohl, W.R. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 2015, 29, 215–239. [CrossRef] [PubMed]

6. Hérodin, F.; Roy, L.; Grenier, N.; Delaunay, C.; Bauge, S.; Vaurijoux, A.; Gregoire, E.; Martin, C.; Alonso, A.; Mayol, L.F.; et al. Antipapoptotic cytokines in combination with pegfilgrastim soon after irradiation mitigate myelosuppression in nonhuman primates exposed to high radiation dose. Exp. Hematol. 2007, 35, 1172–1181. [CrossRef] [PubMed]

7. Hirouchi, T.; Ito, K.; Nakano, M.; Monzen, S.; Yoshino, H.; Chiba, M.; Hazawa, M.; Nakano, A.; Ishikawa, J.; Yamaguchi, M.; et al. Mitigative effects of a combination of multiple pharmaceutical drugs on the survival of mice exposed to lethal ionizing radiation. Curr. Pharm. Biotechnol. 2016, 17, 190–199. [CrossRef]

8. Singh, V.K.; Newman, V.L.; Seed, T.M. Colony-stimulating factors for the treatment of the hematopoietic compartment of the acute radiation syndrome (H-ARS): A review. Cytokine 2015, 71, 22–37. [CrossRef] [PubMed]

9. Dunlap, J.; Minami, E.; Bhagwat, A.A.; Keister, D.L.; Stacey, G. Nodule development induced by mutants of Bradyrhizobium japonicum defective in cyclic β-glucan synthesis. Mol. Plant Microbe Interact. 1996, 9, 546–555. [CrossRef] [PubMed]

10. Magnani, M.; Castro-Gomez, R.H.; Aoki, M.N.; Gregorio, E.P.; Libos, F.; Watanabe, M.A.E. Effects of carboxymethyl-glucan from Saccharomyces cerevisiae on the peripheral blood of patients with advanced prostate cancer. Exp. Ther. Med. 2010, 5, 859–862. [CrossRef]

11. Ohno, N.; Miura, N.N.; Nakajima, M.; Yadomae, T. Antitumor 1,3-β-glucan from cultured fruit body of Sparassis crispa. Biol Pharm. Bull. 2000, 23, 866–872. [CrossRef] [PubMed]

12. Chang, R. Bioactive polysaccharides from traditional Chinese medicine herbs as anticancer adjuvants. J. Altern. Complement. Med. 2002, 8, 559–565. [CrossRef] [PubMed]

13. Patchen, M.L.; MacVittie, T.J. Dose-dependent responses of murine pluripotent stem cells and myeloid and erythroid progenitor cells following administration of the immunomodulating agent glucan. Immunopharmacology 1983, 5, 303–313. [CrossRef]

14. Pospíšil, M.; Jarý, J.; Netiková, J.; Marek, M. Glucan-induced enhancement of hematopoietic recovery in γ-irradiated mice. Experientia 1982, 38, 1232–1234. [CrossRef] [PubMed]

15. Pospíšil, M.; Šandula, J.; Pipalová, I.; Hofer, M.; Viklická, Š. Hemopoiesis stimulating and radioprotective effects of carboxymethylglucan. Physiol. Res. 1991, 40, 377–380. [PubMed]

16. Hofer, M.; Pospíšil, M.; Viklická, Š.; Pipalová, I.; Holá, J.; Šandula, J. Effects of postirradiation carboxymethylglucan administration in mice. Int. J. Immunopharmacol. 1995, 17, 167–174. [CrossRef]

17. Hofer, M.; Pospíšil, M.; Pipalová, I.; Holá, J.; Šandula, J. Haemopoiesis-enhancing effects of repeatedly administered carboxymethylglucan in mice exposed to fractionated irradiation. Folia Biol. 1995, 41, 249–256. [CrossRef]

18. Hofer, M.; Pospíšil, M. Glucan as stimulator of hematopoiesis in normal and γ-irradiated mice. A survey of the authors’ own results. Int. J. Immunopharmacol. 1997, 19, 607–609. [CrossRef]

19. Patchen, M.L.; MacVittie, T.J. Macrophages and Natural Killer Cells; Borman, J.J., Sorkin, E., Eds.; Plenum Publishing Corporation: New York, NY, USA, 1982; pp. 267–272.

20. Patchen, M.L.; MacVittie, T.J. Stimulated hemopoiesis and enhanced survival following glucan treatment in sublethally and lethally irradiated mice. Int. J. Immunopharmacol. 1985, 7, 923–932. [CrossRef]
21. Patchen, M.L.; MacVittie, T.J.; Wathen, L.M. Effects of pre- and post-irradiation glucan treatment on pluripotent stem cells, granulocyte, macrophage and erythroid progenitor cells, and hemopoietic stromal cells. *Experientia* 1984, 40, 1240–1244. [CrossRef] [PubMed]

22. Patchen, M.L.; MacVittie, T.J.; Brook, I. Glucan-induced hemopoietic and immune stimulation: Therapeutic effects in sublethally and lethally irradiated mice. *Meth. Find. Exp. Clin. Pharmacol.* 1986, 8, 151–155.

23. Patchen, M.L.; D’Alesandro, M.M.; Brook, I.; Blakely, W.F.; MacVittie, T.J. Glucan: Mechanisms involved in its “radioprotective” effect. *J. Leukoc. Biol.* 1987, 42, 95–105. [PubMed]

24. Patchen, M.L.; Brook, I.; Elliott, T.B.; Jackson, W.E. Adverse effects of pefloxacin in irradiated C3H/HeN mice: Correction with glucan therapy. *Antimicrob. Agents Chemotherapy* 1993, 37, 1882–1889. [CrossRef] [PubMed]

25. Pospíšil, M.; Netíková, J.; Pipalová, I.; Jarý, J. Combined radioprotection by preirradiation peroral cystamine and postirradiation glucan administration. *Folia Biol.* 1991, 37, 117–124.

26. Pospíšil, M.; Hofer, M.; Pipalová, I.; Viklická, Š.; Netíková, J.; Šandula, J. Enhancement of hemopoietic recovery in γ-irradiated mice by the joint use of diclofenac, an inhibitor of prostaglandin synthesis, and glucan, a macrophage activator. *Exp. Hematol.* 1992, 20, 891–896. [PubMed]

27. Hofer, M.; Pospíšil, M.; Viklická, Š.; Vacek, A.; Pipalová, I.; Bartoníčková, A. Hematopoietic recovery in repeatedly irradiated mice can be enhanced by a repeatedly administered combination of diclofenac and glucan. *J. Leukoc. Biol.* 1993, 53, 185–189. [PubMed]

28. Cramer, D.E.; Allendorf, D.J.; Baran, J.T.; Hansen, R.; Marroquin, J.; Li, B.; Ratajczak, J.; Ratajczak, M.Z. β-glucan ameliorates γ-rays induced oxidative injury in jury in male Swiss albino rats. *Pak. J. Zool.* 2011, 43, 933–939.

29. Pillai, T.G.; Devi, P.U. Mushroom β glucan: Potential candidate for post irradiation protection. *Mutat. Res. Genet. Toxicol. Environ. Mutagen.* 2013, 751, 109–115. [CrossRef] [PubMed]

30. Rondanelli, M.; Opizzi, A.; Monteferrario, F. The biological activity of β-glucans. *Minerva Med.* 2009, 3, 237–245.

31. Whitnall, M.H.; Elliott, T.B.; Harding, R.A.; Inal, C.E.; Landauer, M.R.; Wilhelmsen, C.L.; McKinney, L.; Miner, V.L.; Jackson, W.E.; Loria, R.M.; et al. Androstenediol stimulates myelopoiesis and enhances resistance to infection in γ-irradiated mice. *Int. J. Immunopharmacol.* 2000, 22, 1–14. [CrossRef]

32. Whitnall, M.H.; Inal, C.E.; Jackson, W.E.; Miner, V.L.; Villa, V.; Seed, T.M. In vivo radioprotection by 5-androstenediol: Stimolation of the innate immune system. *Radiat. Res.* 2001, 156, 283–293. [CrossRef]

33. Whitnall, M.H.; Wilhelmsen, C.L.; McKinney, L.; Miner, V.; Seed, T.M.; Jackson, W.E. Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice. *Immunopharmacol.* 2002, 24, 595–626. [CrossRef] [PubMed]

34. Singh, V.K.; Shafran, R.L.; Inal, C.E.; Jackson, W.E.; Whitnall, M.H. Effects of whole-body γ irradiation and 5-androstenediol administration on serum γ-CSF. *Immunopharmacol.* 2005, 27, 521–534. [CrossRef] [PubMed]

35. Whitnall, M.H.; Villa, V.; Seed, T.M.; Banjack, J.; Miner, V.; Lewbart, M.L.; Dowding, C.A.; Jackson, W.E. Molecular specificity of 5-androstenediol as a systemic radioprotectant in mice. *Immunopharmacol.* 2005, 27, 15–32. [CrossRef] [PubMed]
42. Stickney, D.R.; Dowding, C.; Garsd, A.; Ahlem, C.; Whitnall, M.; McKeon, M.; Reading, C.; Frincke, J. 5-androstenediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression. *Int. Immunopharmacol.* 2006, 6, 1706–1713. [CrossRef] [PubMed]

43. Stickney, D.R.; Dowding, C.; Authier, S.; Garsd, A.; Onizuka-Handa, N.; Reading, C.; Frincke, J.M. 5-androstenediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression. *Int. Immunopharmacol.* 2007, 7, 500–505. [CrossRef] [PubMed]

44. Xiao, M.; Inal, C.E.; Parekh, V.L.; Chang, C.M.; Whitnall, M.H. 5-androstenediol promotes survival of γ-irradiated human hematopoietic progenitors through induction of nuclear factor-κB activation and granulocyte colony-stimulating factor expression. *Mol. Pharmacol.* 2007, 72, 370–379. [CrossRef] [PubMed]

45. Singh, V.K.; Grace, M.B.; Jacobsen, K.O.; Chang, C.M.; Parekh, V.L.; Inal, C.E.; Shafran, R.L.; Whitnall, A.D.; Kao, T.C.; Jackson, W.E.; et al. Administration of 5-androstenediol to mice: Pharmacokinetics and cytokine gene expression. *Exp. Mol. Pathol.* 2008, 84, 178–188. [CrossRef] [PubMed]

46. Grace, M.B.; Singh, V.K.; Rhee, J.G.; Jackson, W.E.; Kao, T.C.; Whitnall, M.H. 5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis. *J. Radiat. Res.* 2012, 53, 840–853. [CrossRef] [PubMed]

47. Arts-Kaya, F.S.F.; Visser, T.P.; Arshad, S.; Frincke, J.; Stickney, D.R.; Reading, C.L.; Wagemaker, G. 5-androstene-3β,17β-diol promotes recovery of immature hematopoietic cells following myelosuppressive radiation and synergizes with thrombopoietin. *Int. J. Radiat. Oncol. Biol. Phys.* 2012, 84, E401–E407. [CrossRef] [PubMed]

48. Kim, J.S.; Jang, W.S.; Lee, S.; Son, Y.; Park, S.; Lee, S.S. A study of the effects of sequential injection of 5-androstenediol on radiation-induced myelosuppression in mice. *Arch. Pharm. Res.* 2015, 38, 1213–1222. [CrossRef] [PubMed]

49. Singh, V.K.; Newman, V.L.; Romaine, P.L.P.; Wise, S.Y.; Seed, T.M. Radiation countermeasure agents: An update (2011–2014). *Exp. Opin. Ther. Pat.* 2014, 24, 1229–1255. [CrossRef] [PubMed]

50. Stickney, D.R.; Groothuis, J.R.; Ahlem, C.; Kennedy, M.; Miller, B.S.; Onizuka-Handa, N.; Schlangen, K.M.; Destiche, D.; Reading, C.; Garsd, A.; et al. Preliminary clinical findings on Nemunne as a potential treatment for acute radiation syndrome. *J. Radiol. Prot.* 2010, 30, 687–698. [CrossRef] [PubMed]

51. Ainsworth, E.J.; Hatch, M.H. Decreased X-ray mortality in endotoxin-treated mice. *Radiat. Res.* 1957, 9, 84. [PubMed]

52. Hanks, G.E.; Ainsworth, E.J. Endotoxin protection and colony-forming units. *Radiat. Res.* 1967, 32, 367–382. [CrossRef] [PubMed]

53. Opal, S.M. Endotoxins and other sepsis triggers. *Contrib. Nephrol.* 2010, 67, 14–24. [PubMed]

54. Bertok, L.; Sztanyik, L.B.; Bertok, L. The effect of kanamycin treatment of rats on the development of gastrointestinal syndrome of radiation disease. *Acta Microbiol. Hung.* 1992, 39, 155–158. [PubMed]

55. Fedoročko, P.; Brezáni, P. Radioprotection of mice by the bacterial extract Broncho-Vaxom—Comparison of survival of 5 inbred mouse strains. *Int. J. Immunother.* 1992, 8, 185–190. [PubMed]

56. Fedoročko, P.; Brezáni, P.; Macková, N.O. Radioprotection of mice by the bacterial extract Broncho-Vaxom®—Hematopoietic stem-cells and survival enhancement. *Int. J. Radiat. Biol.* 1992, 61, 511–518. [CrossRef] [PubMed]

57. Macková, N.O.; Fedoročko, P. Preirradiation hematological effects of the bacterial extract Broncho-Vaxom® and postirradiation acceleration recovery from radiation-induced hematopoietic depression. *Drug Exp. Clin. Res.* 1993, 19, 143–150. [PubMed]

58. Fedoročko, P.; Macková, N.O.; Kopka, M. Administration of the bacterial extract Broncho-Vaxom® enhances radiation recovery and myelopoietic regeneration. *Immunopharmacology* 1994, 28, 163–170. [CrossRef]

59. Fedoročko, P.; Brezáni, P.; Macková, N.O. Radioprotective effects of WR-2721, Broncho-Vaxom® and their combinations—Survival, myelopoietic restoration and induction of colony-stimulating activity in mice. *Int. J. Immunopharmacol.* 1994, 16, 177–184. [CrossRef] [PubMed]

60. Macková, N.O.; Fedoročko, P. Combined radioprotective effect of Broncho-Vaxom® and WR-2721 on hematopoiesis and circulating blood cells. *Neoplasma* 1995, 42, 25–30. [PubMed]

61. Saada, H.N.; Azab, K.S.; Zahran, A.M. Post-irradiation effect of Broncho-Vaxom, OM-85 BV, and its relationship to anti-oxidant activities. *Pharmazie* 2001, 56, 654–656. [PubMed]
62. Madonna, G.S.; Ledney, G.D.; Elliott, T.B.; Brook, I.; Ulrich, J.T.; Myers, K.R.; Patchen, M.L.; Walker, R.I. Trehalose dimycolate enhances resistance to infection in neutropenic animals. Infect. Immun. 1989, 57, 2495–2501. [PubMed]

63. Madonna, G.S.; Ledney, G.D.; Moore, M.M.; Elliott, T.B.; Brook, I. Treatment of mice with sepsis following irradiation and trauma with antibiotics and synthetic trehalose dicomynoloylate (S-TDCM). J. Trauma 1991, 31, 316–325. [CrossRef] [PubMed]

64. Crescenti, E.; Croci, M.; Medina, V.; Sambucco, L.; Bergoc, R.; Rivera, E. Radioprotective potential of a novel therapeutic formulation of oligoelements Se, Zn, Mn plus Lachesis muta venom. J. Radiat. Res. 2009, 50, 537–544. [CrossRef] [PubMed]

65. Crescenti, E.J.V.; Medina, V.A.; Croci, M.; Sambuco, L.A.; Prestifilippo, J.P.; Elverdin, J.C.; Bergoc, R.M.; Rivera, E.S. Radioprotection of sensitive rat tissues by oligoelements Se, Zn, Mn plus Lachesis muta venom. J. Radiat. Res. 2011, 52, 557–567. [CrossRef] [PubMed]

66. Liu, W.; Chen, Q.; Wu, S.; Xia, X.C.; Wu, A.Q.; Cui, F.M.; Gu, Y.P.; Zhang, X.G.; Cao, J.P. Radioprotector WR-2721 and mitigating peptidoglycan synergistically promote mouse survival through the amelioration of intestinal and bone marrow damage. J. Radiat. Res. 2015, 56, 278–286. [CrossRef] [PubMed]

67. Li, N.; Shen, X.R.; Liu, Y.M.; Zhang, J.L.; He, Y.; Liu, Q.; Jiang, D.W.; Zong, J.; Li, J.M.; Hou, D.Y.; et al. Isolation, characterization, and radiation protection of Sipunculus nudus L. polysaccharide. Int. J. Biol. Macromol. 2016, 83, 288–296. [CrossRef] [PubMed]

68. Cui, F.M.; Li, M.; Chen, Y.J.; Liu, Y.M.; He, Y.; Jiang, D.W.; Tong, J.; Li, J.X.; Shen, X.R. Protective effects of polysaccharides from Sipunculus nudus on beagle dogs exposed to γ-radiation. PLoS ONE 2014, 9, e104299. [CrossRef] [PubMed]

69. Jiang, S.Q.; Shen, X.R.; Liu, Y.M.; He, Y.; Jiang, D.W.; Chen, W. Radioprotective effects of Sipunculus nudus L. polysaccharide combined with WR-2721, rhIL-11 and rhG-CSF on radiation-injured mice. J. Radiat. Res. 2015, 56, 515–522. [CrossRef] [PubMed]

70. Hanson, W.R.; Thomas, C. 16,16-dimethyl prostaglandin-E2 increases survival of murine intestinal stem-cells when given before photon radiation. Radiat. Res. 1983, 96, 393–398. [CrossRef] [PubMed]

71. Hanson, W.R. Radiation protection of murine intestine by WR-2721, 16,16-dimethyl prostaglandin-E2, and the combination of both agents. Radiat. Res. 1987, 111, 361–373. [CrossRef] [PubMed]

72. Hanson, W.R.; Houseman, K.A.; Nelson, A.K.; Collins, P.W. Radiation protection of the murine intestine by misoprostol, a prostaglandin-E1 analog, given alone or with WR-2721, is stereospecific. Prostagl. Leukot. Essent. Fatty Acids 1988, 32, 101–105.

73. Satoh, H.; Amagase, K.; Ebara, S.; Akiba, Y.; Takeuchi, K. Cyclooxygenase (COX)-1 and COX-2 both play an important role in the protection of the duodenal mucosa in cats. J. Pharmacol. Exp. Ther. 2013, 344, 189–195. [CrossRef] [PubMed]

74. Mahmud, T.; Scott, D.L.; Bjarnason, I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann. Rheum. Dis. 1996, 55, 211–231. [CrossRef] [PubMed]

75. Hanson, W.R.; Ainsworth, E.J. 16,16-dimethyl prostaglandin E

76. Lu, L.; Pelus, L.M.; Broxmeyer, H.E. Modulation of the expression of HLA-DR (Ia) antigens and the proliferation of human erythroid (BFU-E) and multipotential (CFU-GEMM) progenitor cells by prostaglandin E2. Exp. Hematol. 1984, 12, 741–748. [PubMed]

77. Lu, L.; Pelus, L.M.; Piacibello, W.; Moore, M.A.S.; Hu, W.; Broxmeyer, H.E. Prostaglandin E acts at two levels to enhance colony formation in vitro by erythroid (BFU-E) progenitor cells. Exp. Hematol. 1987, 15, 765–771. [PubMed]

78. Kurland, J.; Moore, M.A.S. Modulation of hemopoiesis by prostaglandins. Exp. Hematol. 1977, 7, 119–126.

79. Gentile, P.; Byer, D.; Pelus, L.M. In vivo modulation of murine myelopoiesis following intravenous administration of prostaglandin E2. Blood 1983, 62, 1100–1107. [PubMed]

80. Frölich, J.C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol. Sci. 1997, 18, 30–34. [CrossRef] [PubMed]

81. Furuta, Y.; Hunter, N.; Barkley, T.; Hall, E.; Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. Radiat. Res. 1988, 48, 3008–3013.
82. Kozubík, A.; Pospíšil, M.; Netliková, J. The stimulatory effect of single-dose pre-irradiation administration of indomethacin and diclofenac on hematopoietic recovery in the spleen of γ-irradiated mice. *Studia Biophys.* 1989, 131, 93–101.

83. Nishiguchi, I.; Furuta, Y.; Hunter, N.; Murray, D.; Milas, L. Radioprotection of haematopoietic tissue by indomethacin. *Radiat. Res.* 1990, 122, 188–192. [CrossRef] [PubMed]

84. Kozubík, A.; Hofmanová, J.; Holá, J.; Netíková, J. The effect of nordihydroguaiaretic acid, an inhibitor of prostaglandin and leukotriene biosynthesis, on hematopoiesis of γ-irradiated mice. *Exp. Hematol.* 1993, 21, 138–142. [PubMed]

85. Pospíšil, M.; Netíková, J.; Kozubík, A. Enhancement of haemopoietic recovery by indomethacin after sublethal whole-body γ irradiation. *Acta Radiol. Oncol.* 1986, 25, 195–198. [CrossRef] [PubMed]

86. Pospíšil, M.; Netíková, J.; Kozubík, A.; Pipalová, I. Effect of indomethacin, diclofenac sodium and sodium salicylate on peripheral blood cell counts in sublethally γ-irradiated mice. *Strahlenther. Onkol.* 1989, 165, 627–631. [PubMed]

87. Serushago, B.A.; Tanaka, K.; Koga, Y.; Taniguchi, K.; Nomoto, K. Positive effects of indomethacin on restoration of splenic nucleated cell population in mice given sublethal irradiation. *Immunopharmacology* 1987, 14, 21–26. [PubMed]

88. Sklobovska, I.E.; Zhavoronkov, L.P.; Dubovik, R.V. Haemostimulating efficiency of prostaglandin biosynthesis inhibitors in conditions of fractionated irradiation. *Radiobiologiya* 1986, 26, 185–188.

89. Hofer, M.; Pospíšil, M.; Pipalová, I. Radioprotective effects of flurbiprofen. *Folia Biol.* 1996, 42, 267–269.

90. Hofer, M.; Pospíšil, M.; Pipalová, I.; Holá, J. Modulation of haemopoietic radiation response of mice by diclofenac in fractionated treatment. *Physiol. Res.* 1996, 45, 213–220. [PubMed]

91. Hofer, M.; Pospíšil, M.; Tkadleček, L.; Vilíkčá, Š.; Pipalová, I. Low survival of mice following lethal γ-irradiation after administration of inhibitors of prostaglandin synthesis. *Physiol. Res.* 1992, 41, 157–161. [PubMed]

92. Floersheim, G.L. Allopurinol, indomethacin and riboflavin enhance radiation lethality in mice. *Radiat. Res.* 1994, 139, 240–247. [CrossRef] [PubMed]

93. Hofer, M.; Pospíšil, M.; Hoferová, Z.; Weiterová, L.; Komurkó, D. Stimulatory action of cyclooxygenase inhibitors on hematopoiesis. A review. *Molecules* 2012, 17, 5615–5625. [CrossRef] [PubMed]

94. Hofer, M.; Pospíšil, M.; Znojil, V.; Holá, J.; Vacek, A.; Weiterová, L.; Štreitová, D.; Kozubík, A. Meloxicam, a cyclooxygenase-2 inhibitor, supports hematopoietic recovery in γ-irradiated mice. *Radiat. Res.* 2006, 166, 556–560. [CrossRef] [PubMed]

95. Hofer, M.; Pospíšil, M.; Znojil, V.; Holá, J.; Vacek, A.; Štreitová, D. Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of G-CSF and might be usable as an auxiliary means in G-CSF therapy. *Physiol. Res.* 2008, 57, 307–310. [PubMed]

96. Hofer, M.; Pospíšil, M.; Dušek, L.; Hoferová, Z.; Weiterová, L. A single dose of an inhibitor of cyclooxygenase 2, meloxicam, administered shortly after irradiation increases survival of lethally irradiated mice. *Radiat. Res.* 2011, 176, 269–272. [CrossRef] [PubMed]

97. Hoggatt, J.; Singh, P.; Sampath, J.; Pelus, L.M. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. *Blood* 2009, 113, 5444–5455. [CrossRef] [PubMed]

98. Hoggatt, J.; Singh, P.; Stilger, K.N.; Plett, P.A.; Sampson, C.H.; Chua, H.L.; Orcschell, C.M.; Pelus, L.M. Recovery from hematopoietic injury by modulating prostaglandin E2 signaling post-irradiation. *Blood Cells Mol. Dis.* 2013, 50, 147–153. [CrossRef] [PubMed]

99. Arora, R.; Gupta, D.; Chawla, R.; Sagar, R.; Sharma, A.; Kumar, R.; Prasad, J.; Singh, S.; Samanta, N.; Sharma, R.K. Radioprotection by plant products: Present status and future prospects. *Phytother. Res.* 2005, 19, 1–22. [CrossRef] [PubMed]

100. Liu, W.C.; Wang, S.C.; Tsai, M.L.; Chen, M.C.; Wang, Y.C.; Hong, J.H.; McBride, W.H.; Chiang, C.S. Protection against radiation-induced bone marrow and intestinal injuries by *Cordyceps sinensis*, a Chinese herbal medicine. *Radiat. Res.* 2006, 166, 900–907. [CrossRef] [PubMed]

101. Gupta, M.L.; Sankwar, S.; Verma, S.; Devi, M.; Samanta, N.; Agarwala, P.K.; Kumar, R.; Singh, P.K. Whole-body protection to lethally irradiated mice by oral administration of semipurified fraction of *Podophyllum hexandrum* and post irradiation treatment with *Picrorhiza kurroa*. *Tokai J. Exp. Clin. Med.* 2008, 33, 6–12. [PubMed]
102. Lata, M.; Prasad, J.; Singh, S.; Kumar, R.; Singh, L.; Chaudhary, P.; Arora, R.; Chawla, R.; Tyagi, S.; Soni, N.L.; et al. Whose body protection against lethal ionizing radiation in mice by REC-2001: A semi-purified fraction of Podophyllum hexandrum. Phytomedicine 2009, 16, 47–55. [CrossRef] [PubMed]

103. Pratheeshkumar, P.; Kuttan, G. Protective role of Vernonia cinerea L. against γ radiation-induced immunosuppression and oxidative stress in mice. Hum. Exp. Toxicol. 2011, 30, 1022–1038. [CrossRef]

104. Shakeri-Boroujeni, A.; Mozdaravi, H.; Mahmmoudzadeh, M.; Faeghi, F. Potent radioprotective effect of herbal immunomodulator drug (IMOD) on mouse bone marrow erythrocytes as assayed by the micronucleus test. Int. J. Radiat. Res. 2016, 14, 221–228. [CrossRef]

105. Wasserman, T.H.; Brizel, D.M. The role of amifostine as a radioprotector. Oncology N. Y. 2001, 15, 1349–1354.

106. Upadhyay, S.N.; Dwarkanath, B.S.; Ravindranath, T.; Mathew, T.L. Chemical radioprotectors. Def. Sci. J. 2005, 55, 402–425. [CrossRef]

107. Upadhyay, S.N.; Ghose, A. Radioprotection by chemical means with the help of combined regimen radio-protectors—A short review. J. Ind. Chem. Soc. 2017, 94, 321–325.

108. Mell, I.K.; Movsas, B. Pharmacologic normal tissue protection in clinical radiation oncology: Focus on amifostine. Expert Opin. Drug Met. 2008, 4, 1341–1350. [CrossRef] [PubMed]

109. Gu, J.D.; Zhu, S.W.; Li, X.B.; Wu, H.; Li, Y.; Hua, F. Effects of amifostine in head and neck cancer patients treated with radiotherapy: A systematic review and meta-analysis based on randomized controlled trials. PLoS ONE 2014, 9, e95968. [CrossRef] [PubMed]

110. Singh, V.K.; Fatamani, O.O.; Wise, S.Y.; Newman, V.L.; Romaine, L.P.; Seed, T.M. The potentiation of the radioprotective efficacy of two medical countermeasures, γ-tocotrienol and amifostine, by a combination prophylactic modality. Radiat. Prot. Dosim. 2016, 172, 302–310. [CrossRef] [PubMed]

111. Weiss, J.F.; Landauer, M.R. Radioprotection by antioxidants. Int. J. Mol. Sci. 2017, 18, 1385.

112. Kamal-Eldin, A.; Appelqvist, L.A. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 1996, 31, 671–701. [CrossRef] [PubMed]

113. Palozza, P.; Simone, R.; Picci, N.; Buzzoni, L.; Ciliberti, N.; Manfredini, S.; Vertuani, S. Design, synthesis, and antioxidant potency of novel α-tocopherol analogues in isolated membranes and intact cells. Free Radic. Biol. Med. 2008, 44, 1452–1454. [CrossRef] [PubMed]

114. Sen, C.K.; Khanna, S.; Roy, S.; Packer, L. Molecular basis of vitamin E action tocotrienol potently inhibits glutamate-induced pp60c-src kinase activation and death of HT4 neuronal cells. J. Biol. Chem. 2000, 275, 13049–13055. [CrossRef] [PubMed]

115. Roy, R.M.; Petrella, M.; Shateri, H. Effects of administering tocopherol after irradiation on survival and proliferation of murine lymphocytes. PharmacoL Ther. 1988, 39, 393–395. [CrossRef]

116. Ueno, M.; Inano, H.; Onoda, M.; Murase, H.; Ikota, N.; Kagiya, T.V.; Anzai, K. Modification of mortality and tumorigenesis by tocopherol-monoglucoside (TMG) administered after irradiation in mice and rats. Radiat. Res. 2009, 172, 519–524. [CrossRef] [PubMed]

117. Kumar, K.S.; Srinivasan, V.; Toles, R. Nutritional approaches to radioprotection. Vitamin Е. Mil. Med. 2002, 167, 57–59. [PubMed]

118. Satyamitra, M.; Uma Devi, P.; Murase, H.; Kagiya, V.T. In vivo postirradiation protection by a vitamin E analog, α-TMG. Radiat. Res. 2003, 160, 655–661. [CrossRef] [PubMed]

119. Cherdynseteva, N.; Shishkina, A.; Butorin, L.; Murase, H.; Gervas, P.; Kagiya, T.V. Effect of tocopherol-monoglucoside (TMG), a water-soluble glycosylated derivate of vitamin Е, on hematopoietic recovery in irradiated mice. J. Radiat. Res. 2005, 46, 37–41. [CrossRef] [PubMed]

120. Sen, C.K.; Khanna, S.; Roy, S.; Packer, L. Molecular basis of vitamin E action tocotrienol potently inhibits glutamate-induced pp60c-src kinase activation and death of HT4 neuronal cells. J. Biol. Chem. 2000, 275, 13049–13055. [CrossRef] [PubMed]

121. Kamal-Eldin, A.; Appelqvist, L.A. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 1996, 31, 671–701. [CrossRef] [PubMed]

122. Singh, V.K.; Brown, D.S.; Kao, T.C. Tocopherol succinate: A promising radiation countermeasure. Int. Immunopharmacol. 2009, 9, 1423–1430. [CrossRef] [PubMed]

123. Singh, P.K.; Wise, S.Y.; Ducey, E.J.; Fatamani, O.O.; Elliott, T.B.; Singh, V.K. α-tocopherol succinate protects mice against radiation-induced intestinal injury. Radiat. Res. 2012, 177, 133–145. [CrossRef] [PubMed]

124. Singh, P.K.; Wise, S.Y.; Ducey, E.J.; Brown, D.S.; Singh, V.K. Radioprotective efficacy of α-tocopherol succinate is mediated through granulocyte-colony stimulating factor. Cytokine 2011, 56, 411–421. [CrossRef] [PubMed]
125. Palozza, P.; Verdecchia, S.; Avanzi, L.; Vartuani, S.; Serini, S.; Manfredini, S. Comparative antioxidant activity of tocotrienols and the novel chromanyl-polyisoprenyl molecule PeAox-6 in isolated membranes and intact cells. *Mol. Cell Biochem.* 2006, 287, 21–32. [CrossRef] [PubMed]

126. Li, X.H.; Fu, D.D.; Latif, N.H.; Mullaney, C.P.; Ney, P.H.; Mog, S.R.; Whitnall, M.H.; Srinivasan, V.; Xiao, M. δ-tocotrienol protects mouse and human hematopoietic progenitors from γ-irradiation through extracellular signal-regulated kinase/mammalian target of rapamycin signaling. *Haematologica* 2010, 95, 1996–2004. [CrossRef] [PubMed]

127. Satyamitra, M.; Kulkarni, S.; Ghosh, S.P.; Mullaney, C.P.; Condiffe, D.; Srinivasan, V. Hematopoietic recovery and amelioration of radiation-induced lethality by the vitamin E isoform, δ-tocotrienol. *Radiat. Res.* 2011, 175, 736–745. [CrossRef] [PubMed]

128. Baliarsingh, S.; Beg, Z.H.; Ahmad, J. The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. *Atherosclerosis* 2005, 182, 367–374. [CrossRef] [PubMed]

129. Kulkarni, S.S.; Ghosh, S.P.; Satyamitra, M.; Mog, S.; Hieber, K.; Romanyukha, L.; Gambles, K.; Toles, R.; Kao, T.C.; Hauer-Jensen, M.; et al. γ-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. *Radiat. Res.* 2010, 173, 738–747. [CrossRef] [PubMed]

130. Ghosh, S.P.; Kulkarni, S.; Hieber, K.; Toles, R.; Romanyukha, L.; Kao, T.C.; Hauer-Jensen, M.; Kumar, K.S. γ-tocotrienol, a tocotrienol as a potent radioprotector. *Int. J. Radiat. Biol.* 2009, 85, 598–606. [CrossRef] [PubMed]

131. Kulkarni, S.; Singh, P.K.; Ghosh, S.P.; Posarac, A.; Singh, V.K. Granulocyte colony-stimulating factor antibody abrogates radioprotective efficacy of γ-tocotrienol, a promising radiation countermeasure. *Cytokine* 2013, 62, 278–285. [CrossRef] [PubMed]

132. Singh, V.K.; Kulkarni, S.; Fatammi, O.O.; Wise, S.Y.; Newman, V.L.; Romaine, P.L.P.; Hendrickson, H.; Gulani, J.; Ghosh, S.P.; Kumar, K.S.; et al. Radioprotective efficacy of γ-tocotrienol in nonhuman primates. *Radiat. Res.* 2018, 185, 285–298. [CrossRef] [PubMed]

133. Singh, V.K.; Beattie, L.A.; Seed, T.M. Vitamin E: Tocopherols and tocotrienols as potential radiation countermeasures. *J. Radiat. Res.* 2013, 54, 973–988. [CrossRef] [PubMed]

134. Singh, V.K.; Hauer-Jensen, M. γ-tocotrienol as a promising countermeasure for acute radiation syndrome: Current status. *Int. J. Mol. Sci.* 2016, 17, 663. [CrossRef] [PubMed]

135. Whanger, P.D. Selenocompounds in plants and animals and their biological significance. *J. Am. Coll. Nutr.* 2002, 21, 223–232. [CrossRef] [PubMed]

136. Weiss, J.F.; Srinivasan, V.; Kumar, K.S.; Landauer, M.R. Radioprotection by metals: Selenium. *Adv. Space Res.* 1992, 12, 223–231. [CrossRef] [PubMed]

137. Kiremidjian-Schumacher, L.; Stotzky, G. Selenium and immune responses. *Environ. Res.* 1987, 42, 227–303. [CrossRef] [PubMed]

138. Weiss, J.F.; Srinivasan, V.; Kumar, K.S.; Landauer, M.R. Radioprotection by metals: Selenium. *Adv. Space Res.* 1992, 12, 223–231. [CrossRef] [PubMed]

139. Weiss, J.F.; Hauer-Jensen, M. γ-tocotrienol as a promising countermeasure for acute radiation syndrome: Current status. *Int. J. Mol. Sci.* 2016, 17, 663. [CrossRef] [PubMed]

140. Whanger, P.D. Selenocompounds in plants and animals and their biological significance. *J. Am. Coll. Nutr.* 2002, 21, 223–232. [CrossRef] [PubMed]

141. Kulkarni, S.S.; Ghosh, S.P.; Satyamitra, M.; Mog, S.; Hieber, K.; Romanyukha, L.; Gambles, K.; Toles, R.; Kao, T.C.; Hauer-Jensen, M.; et al. γ-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. *Radiat. Res.* 2010, 173, 738–747. [CrossRef] [PubMed]

142. Ghosh, S.P.; Kulkarni, S.; Hieber, K.; Toles, R.; Romanyukha, L.; Kao, T.C.; Hauer-Jensen, M.; Kumar, K.S. γ-tocotrienol, a tocotrienol as a potent radioprotector. *Int. J. Radiat. Biol.* 2009, 85, 598–606. [CrossRef] [PubMed]

143. Singh, V.K.; Hauer-Jensen, M. γ-tocotrienol as a promising countermeasure for acute radiation syndrome: Current status. *Int. J. Mol. Sci.* 2016, 17, 663. [CrossRef] [PubMed]

144. Whanger, P.D. Selenocompounds in plants and animals and their biological significance. *J. Am. Coll. Nutr.* 2002, 21, 223–232. [CrossRef] [PubMed]

145. Kiremidjian-Schumacher, L.; Stotzky, G. Selenium and immune responses. *Environ. Res.* 1987, 42, 227–303. [CrossRef] [PubMed]
145. Wambi, C.O.; Sanzari, J.K.; Sayers, C.M.; Nuth, M.; Zhou, Z.Z.; Davis, J.; Finnberg, N.; Lewis-Wambi, J.S.; Ware, J.H.; El-Deiry, W.S.; et al. Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. *Radiat. Res.* 2009, 172, 175–186. [CrossRef] [PubMed]

146. Weiss, J.F.; Landauer, M.R. History and development of radiation-protective agents. *Int. J. Radiat. Biol.* 2009, 85, 539–573. [CrossRef] [PubMed]

147. Han, R.M.; Tian, Y.X.; Liu, Y.; Chen, C.H.; Ai, X.C.; Zhang, J.P.; Skibsted, L.H. Comparison of flavonoids and isoflavonoids as antioxidants. *J. Agric. Food Chem.* 2009, 57, 3780–3785.

148. Zhou, Y.; Mi, M.T. Genistein stimulates hematopoiesis and increases survival in irradiated mice. *J. Radiat. Res.* 2005, 46, 425–433. [CrossRef] [PubMed]

149. Landauer, M.R.; Srinivasan, V.; Seed, T.M. Genistein protects mice from ionizing radiation injury. *J. Appl. Toxicol.* 2003, 23, 379–385. [CrossRef] [PubMed]

150. Davis, T.A.; Clarke, T.K.; Mog, S.R.; Landauer, M.R. Subcutaneous administration of genistein prior to lethal irradiation supports multilineage, hematopoietic progenitor cell recovery and survival. *Int. J. Radiat. Biol.* 2007, 83, 141–151. [CrossRef] [PubMed]

151. Landauer, M.R. Radioprotection by the soy isoflavone genistein. In *Herbal Radiomodulators: Applications in Medicine, Homeland Defence and Space*; Arora, R., Ed.; Cabi Publishing: Wallingford, UK, 2008; pp. 163–173.

152. Day, R.M.; Davis, T.A.; Barshishat-Kupper, M.; McCart, E.A.; Tipton, A.J.; Landauer, M.R. Enhanced hematopoietic protection from radiation by the combination of genistein and captopril. *Int. Immunopharmacol.* 2013, 15, 348–356. [CrossRef] [PubMed]

153. Ha, C.T.; Li, X.H.; Fu, D.D.; Xiao, N.; Landauer, M.R. Genistein nanoparticles protect mouse hematopoietic system and prevent proinflammatory factors after γ irradiation. *Radiat. Res.* 2013, 180, 316–325. [CrossRef] [PubMed]

154. Thorn, J.A.; Jarvis, S.M. Adenosine transporters. *Gen. Pharmacol.* 1996, 27, 613–620. [CrossRef]

155. Gordon, E.L.; Pearson, J.D.; Dickinson, E.S.; Moreau, D.; Slakey, L.H. The hydrolysis of extracellular adenine nucleotides by arterial smooth muscle cells—Regulation of adenosine production at the cell surface. *J. Biol. Chem.* 1989, 264, 18986–18992. [PubMed]

156. Pospíšil, M.; Hofer, M.; Netíková, J.; Víklická, Š.; Pipalová, I.; Bartoníčková, A. Effect of dipyridamole and adenosine monophosphate on cell proliferation in the hematopoietic tissue of normal and γ-irradiated mice. *Experientia* 1992, 48, 253–257.

157. Pospíšil, M.; Hofer, M.; Netíková, J.; Pipalová, I.; Vacek, A.; Bartoníčková, A.; Volenec, K. Elevation of extracellular adenosine induces radioprotective effects in mice. *Radiat. Res.* 1993, 134, 323–330. [CrossRef] [PubMed]

158. Hofer, M.; Pospíšil, M.; Netíková, J.; Znojil, V.; Vácha, J. Enhancement of of haemopoietic spleen colony formation by drugs elevating extracellular adenosine: Effects of repeated in vivo treatment. *Physiol. Res.* 1997, 46, 285–290. [PubMed]

159. Pospíšil, M.; Hofer, M.; Znojil, V.; Vácha, J.; Netíková, J.; Holá, J. Radioprotection of mouse hemopoiesis by dipyridamole and adenosine monophosphate in fractionated treatment. *Radiat. Res.* 1995, 142, 16–22. [CrossRef] [PubMed]

160. Hofer, M.; Pospíšil, M.; Netíková, J.; Znojil, V.; Vácha, J.; Holá, J. Radioprotective efficacy of dipyridamole and AMP combination in fractionated radiation regimen, and its dependence on the time of administration of the drugs prior to irradiation. *Physiol. Res.* 1995, 44, 93–98. [PubMed]

161. Hofer, M.; Pospíšil, M.; Weiterova, L.; Hoferova, Z. The role of adenosine receptor agonists in regulation of hematopoiesis. *Molecules* 2011, 16, 675–685. [CrossRef] [PubMed]

162. Hofer, M.; Pospíšil, M.; Znojil, V.; Holá, J.; Vacek, A.; Štreitová, D. Adenosine A3 receptor agonist acts as a homeostatic regulator of bone marrow hematopoiesis. *Biomed. Pharmacother.* 2007, 61, 356–359. [CrossRef] [PubMed]

163. Hofer, M.; Pospíšil, M.; Šefc, L.; Dušek, L.; Vacek, A.; Holá, J.; Hoferová, Z.; Šteritová, D. Activation of adenosine A3 receptors supports hematopoiesis-stimulating effects of granulocyte colony-stimulating factor in sublethally irradiated mice. *Int. J. Radiat. Biol.* 2010, 86, 649–656. [CrossRef] [PubMed]

164. Hofer, M.; Pospíšil, M.; Dušek, L.; Hoferová, Z.; Weiterová, L. Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A3 receptor agonist on hematopoiesis in sublethally γ-irradiated mice. *Biomed. Pharmacother.* 2011, 65, 427–431. [CrossRef] [PubMed]
182. Delanian, S.; Porcher, R.; Balla-Mekias, S.; Lefaix, J.L. Randomize, placebo-controlled trial of combined petoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. *J. Clin. Oncol.* **2003**, *13*, 2545–2550. [CrossRef] [PubMed]

183. Bey, E.; Prat, M.; Duhamel, P.; Benderitter, M.; Brachet, M.; Trompier, F.; Battaglini, P.; Emou, I.; Boutin, L.; Gourven, M.; et al. Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations. *Wound Repair Regen.* **2010**, *18*, 50–58. [CrossRef] [PubMed]

184. Agay, D.; Scherthan, H.; Forcheron, F.; Grenier, N.; Herodin, F.; Meineke, V.; Drouet, M. Multipotent mesenchymal stem cell grafting to treat cutaneous radiation syndrome: Development of a new minipig model. *Exp. Hematol.* **2010**, *38*, 945–956. [CrossRef] [PubMed]

185. Riccobono, D.; Agay, D.; Francois, S.; Scherthan, H.; Drouet, M.; Forcheron, F. Contribution of intramuscular autologous adipose tissue-derived stem cell injection to treat cutaneous radiation syndrome: Preliminary results. *Health Phys.* **2016**, *111*, 117–126. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).